Clinical trials CAMPATH

CDw52, a 21- to 28-kDa phosphatidylinositol-linked glycoprotein of unclear function, is widely expressed on the cell surface of both B and T lymphocytes (187). Anti-CDw52 mAbs include CAMPATH-1 and its humanized version CAMPATH-1H (187-188). CAMPATH-IH has been evaluated in multiple clinical trials, in which it has shown anticancer efficacy against a variety of lymphoid neoplasms (188-190). However, CAMPATH-IH also induced rapid depletion of both B cells and T cells, resulting in potentially profound immunosuppression (191). 

B. Indications and nse Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Determination of the effectiveness of Campath is based on overall response rates. Comparative randomized trials demonstrating increased survival or clinical benefits such as improvement in disease-related symptoms have not yet been conducted. 

CM-T412 is a chimeric anti-CD4 mAb with a human IgGl. Treatment with cM-T412 in RA patients produced a dose-dependent reduction in circulating CD4 lymphocyte numbers that was protracted especially when given with concomitant methotrexate (62, 63). In open studies, clinical improvement was variable and, as with Campath-IH, did not correlate with peripheral blood CD4 lymphopenia. Three placebo-controlled trials in RA (62, 64, 65) failed to show significant clinical benefit although, similar to CD5-PLUS, the doses used in the placebo-controlled trials were lower than those used in open studies. 

---